Zealand Pharma CEO: Share sale arms us for partnership negotiations

After a study success with short bowel syndrome treatment candidate, the Danish biotech company raised funding by issuing shares, preparing the company’s CEO, Adam Steensberg, to enter dialogs with a number of potential partners.

Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma

With strong phase III data from a study of drug candidate glepaglutide in the bag, Zealand Pharma set off on Tuesday to raise capital -- and did so successfully after a direct share issuance targeting professional investors brought in DKK 786m (USD 105m) on the same day.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs